Total Funding
80
12
Total FundingVenture - Series Unknown raised
Growth Score
-1 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3309097
CytoLogic develops technology for treating cancerous tumors by enhancing the natural immune response to malignant cells.
- Paul M. Thompson: Founder
About the Company
CytoLogic, Inc., a medical device company, focuses on developing and commercializing a technology for treating cancerous tumors. The company’s UNLEASH therapy, which engages selective filtration of blood plasma on a dialysis-type platform, enhances a cancer patient’s natural immune response to malignant cells. Its UNLEASH technology depletes
certain inhibitors of the body’s immune function enabling the patient’s immune system to fight malignant tumors. CytoLogic was founded in 1998 and is based in Boulder, Colorado.
